- Pathology service provider ProPath selects CombiMatrix (CBMX) to "provide its chromosomal microarray analysis testing for miscarriage analysis."
- "For an important group of patients, CMA testing can play a significant role in a comprehensive miscarriage analysis," a ProPath director notes.
- CBMX says the agreement is "yet another validation of the quality of [its] diagnostic services." (PR)
- CBMX +14% premarket.